Maxalt (Rizatriptan Benzoate)

Rizatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of intracranial arteries and blocks the release of pain‑triggering neuropeptides, interrupting the migraine cascade.

The prescribed dose is determined by the treating physician based on individual response and tolerability. Typically, a single oral tablet is taken at the onset of migraine symptoms, with a possible second dose after a specified interval if needed, but exact dosing must follow the prescriber’s instructions.

Safety data for rizatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Maxalt (rizatriptan) has a rapid onset of action, usually within 30 minutes, and a relatively short half‑life compared with some other triptans such as sumatriptan or naratriptan. Efficacy and tolerability are comparable, but individual response varies, so clinicians may choose based on patient history and preference.

Maxalt tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Maxalt is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the first sign of a migraine attack. Do not crush, chew, or split the tablet unless specifically instructed by a healthcare provider.

Serious adverse events, although rare, include chest pain or tightness, severe hypertension, serotonin syndrome when combined with other serotonergic agents, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if any of these symptoms occur.

Maxalt is contraindicated in patients with uncontrolled hypertension, a history of coronary artery disease, recent myocardial infarction or stroke, peripheral vascular disease, and in those taking ergot derivatives or other triptans. It should also be avoided in individuals with known hypersensitivity to rizatriptan.